Evidence map›Paper›PMID 25753197›Full record

ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2015

Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles.

Christopher G England, M Clarke Miller, Ashani Kuttan, John O Trent, Hermann B Frieboes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher G EnglandDept. of Pharmacology & Toxicology, University of Louisville, KY, USA; James Graham Brown Cancer Center, University of Louisville, KY, USA.
M Clarke MillerDept. of Chemistry/Biochemistry, University of North Georgia, GA, USA.
Ashani KuttanJames Graham Brown Cancer Center, University of Louisville, KY, USA; Dept. of Medicine, University of Louisville, KY, USA.
John O TrentJames Graham Brown Cancer Center, University of Louisville, KY, USA; Dept. of Medicine, University of Louisville, KY, USA.
Hermann B FrieboesDept. of Pharmacology & Toxicology, University of Louisville, KY, USA; James Graham Brown Cancer Center, University of Louisville, KY, USA; Dept. of Bioengineering, University of Louisville, KY, USA. Electronic address: hbfrie01@louisville.edu.

Funding

PILOT PROJECT PROGRAMP30GM106396 · NIGMS · UNIVERSITY OF LOUISVILLE · PI EATON, JOHN W · 2013 to 2017
$5.4M
NIGMS NIH HHS 1P30GM106396NIGMS NIH HHS P30 GM106396
6 · The paper itself

Abstract

Gold nanoparticles functionalized with biologically compatible layers may achieve stable drug release while avoiding adverse effects in cancer treatment. We study cisplatin and paclitaxel release from gold cores functionalized with hexadecanethiol (TL) and phosphatidylcholine (PC) to form two-layer nanoparticles, or TL, PC, and high density lipoprotein (HDL) to form three-layer nanoparticles. Drug release was monitored for 14 days to assess long term effects of the core surface modifications on release kinetics. Release profiles were fitted to previously developed kinetic models to differentiate possible release mechanisms. The hydrophilic drug (cisplatin) showed an initial (5-h) burst, followed by a steady release over 14 days. The hydrophobic drug (paclitaxel) showed a steady release over the same time period. Two layer nanoparticles released 64.0±2.5% of cisplatin and 22.3±1.5% of paclitaxel, while three layer nanoparticles released the entire encapsulated drug. The Korsmeyer-Peppas model best described each release scenario, while the simplified Higuchi model also adequately described paclitaxel release from the two layer formulation. We conclude that functionalization of gold nanoparticles with a combination of TL and PC may help to modulate both hydrophilic and hydrophobic drug release kinetics, while the addition of HDL may enhance long term release of hydrophobic drug.

Indexed as

Metal NanoparticlesAntineoplastic AgentsAntineoplastic Agents, PhytogenicCell Line, TumorChemistry, PharmaceuticalCisplatinDelayed-Action PreparationsDrug LiberationGoldHumansHydrophobic and Hydrophilic InteractionsKineticsLipoproteins, HDLModels, ChemicalPaclitaxelPhosphatidylcholinesAntineoplastic AgentsAntineoplastic Agents, PhytogenicCisplatinDelayed-Action PreparationsGoldhexadecanethiolLipoproteins, HDLPaclitaxelPhosphatidylcholinesSulfhydryl CompoundsCisplatinDrug release kineticsDrug release modelingNanotherapyPaclitaxel

Identifiers

PMID25753197
PMCPMC4430429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.